Thursday, February 14, 2013
Publication and contact
Computational approach for
prioritizing potential cancer targets
computational approach that predicts the druggability of cancer-associated
proteins could help prioritize targets in small molecule discovery programs.
The computational approach integrates target class, bioactivity data, protein
structural information and homology modeling to estimate a protein's
druggability. From a list of 479 genes known to be altered in cancer, the
method identified 29 oncogenes and 16 tumor suppressors predicted to be
druggable but for which few or no small molecule ligands had yet been
reported. Next steps include incorporating additional cancer genomic data and
could include prioritizing additional types of gene lists such as those from
synthetic lethal screens in cancer cell lines.
The computational method is freely available through the canSAR
database hosted by The Institute of Cancer Research
(see Cancer target selection pressure, page 1).
Published online Feb. 14, 2013
status not applicable
Patel, M.N. et al. Nat.
Rev. Drug Discov.; published online
Dec. 31, 2012;
Contact: Bissan Al-Lazikani,
The Institute of Cancer Research, London, U.K.
Contact: Paul Workman, same affiliation as above
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]